Prevalence of antinuclear and anti-liver-kidney-microsome type-1 antibodies in patients with chronic hepatitis C in China  

作　　者：BAI Li FENG Zhen-ru LU Hai-ying LI Wen-gang YU Min XU Xiao-yuan 

机构地区：[1]Department of Infectious Diseases,Peking University First Hospital, Beijing 100034, China [2]Department of Clinical Laboratory Peking University First Hospital, Beijing 100034, China

出　　处：《Chinese Medical Journal》2009年第1期5-9,共5页中华医学杂志（英文版）

摘　　要：Background Hepatitis C virus （HCV） infection may induce autoimmune response and autoantibodies can be detected in chronic hepatitis C （CHC） patients. However, the reported positive rate of autoantibodies in CHC patients in China varies considerably. In this study, we investigated the prevalence of antinuclear antibodies （ANA） and anti-liver-kidney-microsome type 1 autoantibodies （anti-LKM-1） in a large cohort of CHC patients, and analyzed the factors related to the presence of the autoantibodies.Methods A total of 360 CHC patients were enrolled in this study. Serum ANA and anti-LKM-1 were detected by indirect immunofluorescence and enzyme-linked immunosorbent assay, respectively. Clinical analysis was performed to disclose the related factors to autoantibody production.Results The prevalence of ANA and anti-LKM-1 in CHC patients was 12.5% （45/360） and 2.5% （9/360）, respectively. Women had a higher prevalence than men （18.9% vs 11.4%, P=0.046）. Patients with positive autoantibodies had lower HCV RNA levels （1.2×10^7 copies/L vs 7.2×10^7 copies/L, P 〈0.05）. Positive ANA was associated with higher serum globulin （P 〈0.05）. Stratified analysis showed that there were no significant differences in age, HCV genotype, disease course, clinical stage, prevalence of cirrhosis and interferon therapy between autoantibody-positive and -negative subgroups.Conclusion Autoantibodies can be induced in the course of CHC, and some CHC patients can even develop autoimmune hepatitis.Background Hepatitis C virus （HCV） infection may induce autoimmune response and autoantibodies can be detected in chronic hepatitis C （CHC） patients. However, the reported positive rate of autoantibodies in CHC patients in China varies considerably. In this study, we investigated the prevalence of antinuclear antibodies （ANA） and anti-liver-kidney-microsome type 1 autoantibodies （anti-LKM-1） in a large cohort of CHC patients, and analyzed the factors related to the presence of the autoantibodies.Methods A total of 360 CHC patients were enrolled in this study. Serum ANA and anti-LKM-1 were detected by indirect immunofluorescence and enzyme-linked immunosorbent assay, respectively. Clinical analysis was performed to disclose the related factors to autoantibody production.Results The prevalence of ANA and anti-LKM-1 in CHC patients was 12.5% （45/360） and 2.5% （9/360）, respectively. Women had a higher prevalence than men （18.9% vs 11.4%, P=0.046）. Patients with positive autoantibodies had lower HCV RNA levels （1.2×10^7 copies/L vs 7.2×10^7 copies/L, P 〈0.05）. Positive ANA was associated with higher serum globulin （P 〈0.05）. Stratified analysis showed that there were no significant differences in age, HCV genotype, disease course, clinical stage, prevalence of cirrhosis and interferon therapy between autoantibody-positive and -negative subgroups.Conclusion Autoantibodies can be induced in the course of CHC, and some CHC patients can even develop autoimmune hepatitis.

关 键 词：hepatitis C  chronic AUTOANTIBODIES hepatitis  autoimmune 

分 类 号：R512.63[医药卫生—内科学]